# AXS-07 PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/axs-07

> AXS-07, sponsored by Axsome Therapeutics, Inc. (AXSM): 3 recorded catalysts.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: quarter only, exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | AXS-07 |
| Codes | AXS-07 |
| Sponsor | Axsome Therapeutics, Inc. (AXSM) https://sec-api.dev/companies/axsm/catalysts |
| Indications |  |
| Modality |  |
| FDA designations | none disclosed |

## Timeline

### Q4 2024: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3.
- First seen 2024-11-12, last confirmed 2024-11-12.
- Press release filed with the SEC (EX-99) (accession 0000950170-24-124546): "Differentiated efficacy and safety profile supported by three Phase 3 clinical trials Ongoing Phase 3 trial evaluating the efficacy and safety of AXS-07 (oral CGRP antagonist non-responders) MOMENTUM Phase 3 (N=1594) Two completed, positive, registrational efficacy and safety trials in >1,800 patients with migraine Rapid, substantial, and sustained pain relief vs. controls in short-term trials AXS-07 well tolerated in open-label extension trial with substantially consistent safety profile as short-term trials Migraine INTERCEPT Phase 3 (N=302) MOVEMENT (OLE) Phase 3 (N=706) PDUFA goal date of January 31, 2025 EMERGE Phase 3 (N=100) Topline Data Anticipated 4Q 2024" https://www.sec.gov/Archives/edgar/data/1579428/000095017024124546/axsm-ex99_2.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-24-124546): "The Company remains on track to announce topline results from the EMERGE trial in the fourth quarter of 2024." https://www.sec.gov/Archives/edgar/data/1579428/000095017024124546/axsm-ex99_1.htm

### Q4 2024: PDUFA date

- Status: scheduled. Date confidence: quarter. Stage: 3.
- First seen 2024-11-12, last confirmed 2024-11-12.
- Press release filed with the SEC (EX-99) (accession 0000950170-24-124546): "Differentiated efficacy and safety profile supported by three Phase 3 clinical trials Ongoing Phase 3 trial evaluating the efficacy and safety of AXS-07 (oral CGRP antagonist non-responders) MOMENTUM Phase 3 (N=1594) Two completed, positive, registrational efficacy and safety trials in >1,800 patients with migraine Rapid, substantial, and sustained pain relief vs. controls in short-term trials AXS-07 well tolerated in open-label extension trial with substantially consistent safety profile as short-term trials Migraine INTERCEPT Phase 3 (N=302) MOVEMENT (OLE) Phase 3 (N=706) PDUFA goal date of January 31, 2025 EMERGE Phase 3 (N=100) Topline Data Anticipated 4Q 2024" https://www.sec.gov/Archives/edgar/data/1579428/000095017024124546/axsm-ex99_2.htm

### January 31, 2025: PDUFA date

- Status: scheduled. Date confidence: exact.
- First seen 2024-11-12, last confirmed 2024-11-12.
- Press release filed with the SEC (EX-99) (accession 0000950170-24-124546): "NDA resubmission for AXS-07 for the treatment of migraine accepted by the FDA with PDUFA goal date of January 31, 2025" https://www.sec.gov/Archives/edgar/data/1579428/000095017024124546/axsm-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-24-124546): "In addition, with the January 31, 2025, PDUFA date for our AXS-07 product candidate for migraine fast approaching, commercial preparations are underway for a timely and successful launch, if approved."" https://www.sec.gov/Archives/edgar/data/1579428/000095017024124546/axsm-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-24-124546): "Migraine: Axsome's New Drug Application (NDA) for AXS-07 for the acute treatment of migraine is currently under review by the FDA with a PDUFA goal date of January 31, 2025." https://www.sec.gov/Archives/edgar/data/1579428/000095017024124546/axsm-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-24-124546): "AXS-07 for migraine, PDUFA goal date (January 31, 2025)" https://www.sec.gov/Archives/edgar/data/1579428/000095017024124546/axsm-ex99_1.htm
- SEC Form 10-Q (accession 0000950170-24-124758): "We resubmitted the NDA for AXS-07 for the acute treatment of migraine to the FDA, which the FDA acknowledged and classified as a Class 2 resubmission, and set a Prescription Drug User Fee Act, or PDUFA, action goal date of January 31, 2025." https://www.sec.gov/Archives/edgar/data/1579428/000095017024124758/axsm-20240930.htm
- SEC Form 10-Q (accession 0000950170-24-124758): "The FDA designated the resubmission as a Class 2 resubmission and set a PDUFA action goal date of January 31, 2025." https://www.sec.gov/Archives/edgar/data/1579428/000095017024124758/axsm-20240930.htm

Calendar months: [January 2025](https://sec-api.dev/fda-calendar/2025-01)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/axs-07.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "AXS-07 PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/axs-07

```bibtex
@misc{secapidev_pdufa_axs_07_20261116,
  title        = {AXS-07 PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/axs-07}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_axs_07_20261116","title":"AXS-07 PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/axs-07","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
